VivoSeq
Neurology

Early-Onset Parkinson's Disease

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Early-onset Parkinson's Disease is an early-stage landscape with 0 programs across 2 companies. The most active players are iRegene Therapeutics Co., Ltd., XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

iRegene Therapeutics Co., Ltd.

0 programs

PreclinicalX

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
Recruiting·IiRegene Therapeutics Co., Ltd.·Phase 1·NCT06608355·6 enrolled
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
Recruiting·XXellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.·Phase 1/2·NCT07166757·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)